Summary

The global market for Autogenous Vaccines was estimated to be worth US$ 472 million in 2024 and is forecast to a readjusted size of US$ 635 million by 2031 with a CAGR of 4.4% during the forecast period 2025-2031.
Autogenous vaccines, also called autologous vaccines, autovaccines, “self” or custom vaccines, are vaccines, which prepared by isolation and destruction of microorganisms in infected individuals and used to provide immunity to the same individual. Generally, indications of autogenous vaccines include resistance of pathogenic microorganisms to antibiotic treatment, ineffective therapy or immune response and lack of commercial vaccines.
Market Driver: The increasing prevalence of bacterial and viral infections in livestock and companion animals is a key driver for the autogenous vaccines market. As antibiotic resistance continues to rise, farmers and veterinarians are turning to customized vaccines as a preventive measure to reduce disease outbreaks and minimize antibiotic usage. Additionally, regulatory support for autogenous vaccines in regions with strict antibiotic use policies, such as the EU and North America, is further boosting market growth. The ability of autogenous vaccines to provide targeted protection against region-specific pathogens makes them an essential tool in modern animal health management.
Market Challenge: Despite the benefits, the autogenous vaccines market faces challenges related to regulatory complexity and manufacturing constraints. Since these vaccines are custom-made for specific pathogens in a limited population, their approval processes and quality control measures vary across different regions, leading to inconsistencies in market access. Furthermore, the production of autogenous vaccines requires specialized facilities and skilled personnel, increasing costs and limiting scalability. Another challenge is the time-sensitive nature of their development, as delays in production can impact their effectiveness in controlling emerging disease outbreaks.
Global Autogenous Vaccines key players include Boehringer Ingelheim, Vaxxinova, Zoetis, Ceva Biovac, Phibro, etc. Global top five manufacturers hold a share over 50%. America is the largest market, with a share about 45%, followed by Europe and Asia Pacific, total have a share over 50 percent. In terms of product, Poultry is the largest segment, with a share over 50%. And in terms of application, the largest application is Large Farms, followed by Small Farms.
This report aims to provide a comprehensive presentation of the global market for Autogenous Vaccines, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Autogenous Vaccines by region & country, by Obejection, and by Application.
The Autogenous Vaccines market size, estimations, and forecasts are provided in terms of sales volume (M Does) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Autogenous Vaccines.
Market Segmentation
By Company
Boehringer Ingelheim
Vaxxinova
Zoetis
Ceva Biovac
Phibro
Elanco
AniCon Labor GmbH
Cambridge Technologies
AVICARE plus
Genova Labs
Addison Biological Laboratory
ACE Laboratory Services
Deltamune
Dyntec
Hygieia Biological Laboratories
Segment by Obejection
Poultry
Fishes
Pigs & Cattle
Other
Segment by Application
Large Farms
Small Farms
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Autogenous Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Obejection, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Autogenous Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Autogenous Vaccines in country level. It provides sigmate data by Obejection, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

ページTOPに戻る

Table of Contents

1 Market Overview
1.1 Autogenous Vaccines Product Introduction
1.2 Global Autogenous Vaccines Market Size Forecast
1.2.1 Global Autogenous Vaccines Sales Value (2020-2031)
1.2.2 Global Autogenous Vaccines Sales Volume (2020-2031)
1.2.3 Global Autogenous Vaccines Sales Price (2020-2031)
1.3 Autogenous Vaccines Market Trends & Drivers
1.3.1 Autogenous Vaccines Industry Trends
1.3.2 Autogenous Vaccines Market Drivers & Opportunity
1.3.3 Autogenous Vaccines Market Challenges
1.3.4 Autogenous Vaccines Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Autogenous Vaccines Players Revenue Ranking (2024)
2.2 Global Autogenous Vaccines Revenue by Company (2020-2025)
2.3 Global Autogenous Vaccines Players Sales Volume Ranking (2024)
2.4 Global Autogenous Vaccines Sales Volume by Company Players (2020-2025)
2.5 Global Autogenous Vaccines Average Price by Company (2020-2025)
2.6 Key Manufacturers Autogenous Vaccines Manufacturing Base and Headquarters
2.7 Key Manufacturers Autogenous Vaccines Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Autogenous Vaccines
2.9 Autogenous Vaccines Market Competitive Analysis
2.9.1 Autogenous Vaccines Market Concentration Rate (2020-2025)
2.9.2 Global 5 and 10 Largest Manufacturers by Autogenous Vaccines Revenue in 2024
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Autogenous Vaccines as of 2024)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Obejection
3.1 Introduction by Obejection
3.1.1 Poultry
3.1.2 Fishes
3.1.3 Pigs & Cattle
3.1.4 Other
3.2 Global Autogenous Vaccines Sales Value by Obejection
3.2.1 Global Autogenous Vaccines Sales Value by Obejection (2020 VS 2024 VS 2031)
3.2.2 Global Autogenous Vaccines Sales Value, by Obejection (2020-2031)
3.2.3 Global Autogenous Vaccines Sales Value, by Obejection (%) (2020-2031)
3.3 Global Autogenous Vaccines Sales Volume by Obejection
3.3.1 Global Autogenous Vaccines Sales Volume by Obejection (2020 VS 2024 VS 2031)
3.3.2 Global Autogenous Vaccines Sales Volume, by Obejection (2020-2031)
3.3.3 Global Autogenous Vaccines Sales Volume, by Obejection (%) (2020-2031)
3.4 Global Autogenous Vaccines Average Price by Obejection (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Large Farms
4.1.2 Small Farms
4.2 Global Autogenous Vaccines Sales Value by Application
4.2.1 Global Autogenous Vaccines Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Autogenous Vaccines Sales Value, by Application (2020-2031)
4.2.3 Global Autogenous Vaccines Sales Value, by Application (%) (2020-2031)
4.3 Global Autogenous Vaccines Sales Volume by Application
4.3.1 Global Autogenous Vaccines Sales Volume by Application (2020 VS 2024 VS 2031)
4.3.2 Global Autogenous Vaccines Sales Volume, by Application (2020-2031)
4.3.3 Global Autogenous Vaccines Sales Volume, by Application (%) (2020-2031)
4.4 Global Autogenous Vaccines Average Price by Application (2020-2031)
5 Segmentation by Region
5.1 Global Autogenous Vaccines Sales Value by Region
5.1.1 Global Autogenous Vaccines Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Autogenous Vaccines Sales Value by Region (2020-2025)
5.1.3 Global Autogenous Vaccines Sales Value by Region (2026-2031)
5.1.4 Global Autogenous Vaccines Sales Value by Region (%), (2020-2031)
5.2 Global Autogenous Vaccines Sales Volume by Region
5.2.1 Global Autogenous Vaccines Sales Volume by Region: 2020 VS 2024 VS 2031
5.2.2 Global Autogenous Vaccines Sales Volume by Region (2020-2025)
5.2.3 Global Autogenous Vaccines Sales Volume by Region (2026-2031)
5.2.4 Global Autogenous Vaccines Sales Volume by Region (%), (2020-2031)
5.3 Global Autogenous Vaccines Average Price by Region (2020-2031)
5.4 North America
5.4.1 North America Autogenous Vaccines Sales Value, 2020-2031
5.4.2 North America Autogenous Vaccines Sales Value by Country (%), 2024 VS 2031
5.5 Europe
5.5.1 Europe Autogenous Vaccines Sales Value, 2020-2031
5.5.2 Europe Autogenous Vaccines Sales Value by Country (%), 2024 VS 2031
5.6 Asia Pacific
5.6.1 Asia Pacific Autogenous Vaccines Sales Value, 2020-2031
5.6.2 Asia Pacific Autogenous Vaccines Sales Value by Region (%), 2024 VS 2031
5.7 South America
5.7.1 South America Autogenous Vaccines Sales Value, 2020-2031
5.7.2 South America Autogenous Vaccines Sales Value by Country (%), 2024 VS 2031
5.8 Middle East & Africa
5.8.1 Middle East & Africa Autogenous Vaccines Sales Value, 2020-2031
5.8.2 Middle East & Africa Autogenous Vaccines Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Autogenous Vaccines Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Autogenous Vaccines Sales Value and Sales Volume
6.2.1 Key Countries/Regions Autogenous Vaccines Sales Value, 2020-2031
6.2.2 Key Countries/Regions Autogenous Vaccines Sales Volume, 2020-2031
6.3 United States
6.3.1 United States Autogenous Vaccines Sales Value, 2020-2031
6.3.2 United States Autogenous Vaccines Sales Value by Obejection (%), 2024 VS 2031
6.3.3 United States Autogenous Vaccines Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Autogenous Vaccines Sales Value, 2020-2031
6.4.2 Europe Autogenous Vaccines Sales Value by Obejection (%), 2024 VS 2031
6.4.3 Europe Autogenous Vaccines Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Autogenous Vaccines Sales Value, 2020-2031
6.5.2 China Autogenous Vaccines Sales Value by Obejection (%), 2024 VS 2031
6.5.3 China Autogenous Vaccines Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Autogenous Vaccines Sales Value, 2020-2031
6.6.2 Japan Autogenous Vaccines Sales Value by Obejection (%), 2024 VS 2031
6.6.3 Japan Autogenous Vaccines Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Autogenous Vaccines Sales Value, 2020-2031
6.7.2 South Korea Autogenous Vaccines Sales Value by Obejection (%), 2024 VS 2031
6.7.3 South Korea Autogenous Vaccines Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Autogenous Vaccines Sales Value, 2020-2031
6.8.2 Southeast Asia Autogenous Vaccines Sales Value by Obejection (%), 2024 VS 2031
6.8.3 Southeast Asia Autogenous Vaccines Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Autogenous Vaccines Sales Value, 2020-2031
6.9.2 India Autogenous Vaccines Sales Value by Obejection (%), 2024 VS 2031
6.9.3 India Autogenous Vaccines Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Boehringer Ingelheim
7.1.1 Boehringer Ingelheim Company Information
7.1.2 Boehringer Ingelheim Introduction and Business Overview
7.1.3 Boehringer Ingelheim Autogenous Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 Boehringer Ingelheim Autogenous Vaccines Product Offerings
7.1.5 Boehringer Ingelheim Recent Development
7.2 Vaxxinova
7.2.1 Vaxxinova Company Information
7.2.2 Vaxxinova Introduction and Business Overview
7.2.3 Vaxxinova Autogenous Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 Vaxxinova Autogenous Vaccines Product Offerings
7.2.5 Vaxxinova Recent Development
7.3 Zoetis
7.3.1 Zoetis Company Information
7.3.2 Zoetis Introduction and Business Overview
7.3.3 Zoetis Autogenous Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 Zoetis Autogenous Vaccines Product Offerings
7.3.5 Zoetis Recent Development
7.4 Ceva Biovac
7.4.1 Ceva Biovac Company Information
7.4.2 Ceva Biovac Introduction and Business Overview
7.4.3 Ceva Biovac Autogenous Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 Ceva Biovac Autogenous Vaccines Product Offerings
7.4.5 Ceva Biovac Recent Development
7.5 Phibro
7.5.1 Phibro Company Information
7.5.2 Phibro Introduction and Business Overview
7.5.3 Phibro Autogenous Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 Phibro Autogenous Vaccines Product Offerings
7.5.5 Phibro Recent Development
7.6 Elanco
7.6.1 Elanco Company Information
7.6.2 Elanco Introduction and Business Overview
7.6.3 Elanco Autogenous Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.6.4 Elanco Autogenous Vaccines Product Offerings
7.6.5 Elanco Recent Development
7.7 AniCon Labor GmbH
7.7.1 AniCon Labor GmbH Company Information
7.7.2 AniCon Labor GmbH Introduction and Business Overview
7.7.3 AniCon Labor GmbH Autogenous Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.7.4 AniCon Labor GmbH Autogenous Vaccines Product Offerings
7.7.5 AniCon Labor GmbH Recent Development
7.8 Cambridge Technologies
7.8.1 Cambridge Technologies Company Information
7.8.2 Cambridge Technologies Introduction and Business Overview
7.8.3 Cambridge Technologies Autogenous Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.8.4 Cambridge Technologies Autogenous Vaccines Product Offerings
7.8.5 Cambridge Technologies Recent Development
7.9 AVICARE plus
7.9.1 AVICARE plus Company Information
7.9.2 AVICARE plus Introduction and Business Overview
7.9.3 AVICARE plus Autogenous Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.9.4 AVICARE plus Autogenous Vaccines Product Offerings
7.9.5 AVICARE plus Recent Development
7.10 Genova Labs
7.10.1 Genova Labs Company Information
7.10.2 Genova Labs Introduction and Business Overview
7.10.3 Genova Labs Autogenous Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.10.4 Genova Labs Autogenous Vaccines Product Offerings
7.10.5 Genova Labs Recent Development
7.11 Addison Biological Laboratory
7.11.1 Addison Biological Laboratory Company Information
7.11.2 Addison Biological Laboratory Introduction and Business Overview
7.11.3 Addison Biological Laboratory Autogenous Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.11.4 Addison Biological Laboratory Autogenous Vaccines Product Offerings
7.11.5 Addison Biological Laboratory Recent Development
7.12 ACE Laboratory Services
7.12.1 ACE Laboratory Services Company Information
7.12.2 ACE Laboratory Services Introduction and Business Overview
7.12.3 ACE Laboratory Services Autogenous Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.12.4 ACE Laboratory Services Autogenous Vaccines Product Offerings
7.12.5 ACE Laboratory Services Recent Development
7.13 Deltamune
7.13.1 Deltamune Company Information
7.13.2 Deltamune Introduction and Business Overview
7.13.3 Deltamune Autogenous Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.13.4 Deltamune Autogenous Vaccines Product Offerings
7.13.5 Deltamune Recent Development
7.14 Dyntec
7.14.1 Dyntec Company Information
7.14.2 Dyntec Introduction and Business Overview
7.14.3 Dyntec Autogenous Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.14.4 Dyntec Autogenous Vaccines Product Offerings
7.14.5 Dyntec Recent Development
7.15 Hygieia Biological Laboratories
7.15.1 Hygieia Biological Laboratories Company Information
7.15.2 Hygieia Biological Laboratories Introduction and Business Overview
7.15.3 Hygieia Biological Laboratories Autogenous Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
7.15.4 Hygieia Biological Laboratories Autogenous Vaccines Product Offerings
7.15.5 Hygieia Biological Laboratories Recent Development
8 Industry Chain Analysis
8.1 Autogenous Vaccines Industrial Chain
8.2 Autogenous Vaccines Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Autogenous Vaccines Sales Model
8.5.2 Sales Channel
8.5.3 Autogenous Vaccines Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer